LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
Combined with rising labor costs, COVID-19, and other challenges, stakeholders say the cuts will negatively impact patient care.
Experts offer advice in a recent commentary article on treating patients who may have monkeypox during the current COVID-19 pandemic.
Georgia health system hospitals are the first to be penalized for failing to update their websites or reply to agency warning letters.
The creation of Global Access Diagnostics aims to expand affordable access to quality tests around the world.
The number of non-COVID-19 tests billed to Medicare during the pandemic has decreased compared to the six-month period before COVID-19.
For the first time, the FDA has granted emergency use authorization for a test to differentiate strains of the SARS-CoV-2 virus.
Three labs, their owner, two lab marketing companies, a fourth lab, and a physician are accused of kickbacks, money laundering, and fraud.
A new AI method developed by the National Cancer Institute could produce results similar to regular CT scans, but without exposing patients to radiation.
Effective June 1, the agency is once more accepting pre-submission requests for all in vitro diagnostics, including non-COVID-19 tests.
With threats and attacks increasing, Congress has tabled a bill that would impose extra penalties on those seeking to harm healthcare staff.